| | | | | Präparat | Packungsgrösse | EFP | PP | SB | TK | Zusammensetzung | Zulassungsinhaber | Kat. | | | | |
---|
|
| | FI | PI | | Casgevy 4-13 x 10e6 cells/ml | | PA | PA | k.A. | | | Vertex Pharmaceuticals (CH) GmbH | A | FB | | G |  |
| | FI | PI | | Ebvallo | | PA | PA | k.A. | | | Pierre Fabre Pharma SA | A | FB | | G |  |
| | FI | PI | | BILAXIN Ophta 6 mg / ml | 5 ml | PA | PA | k.A. | | Augentropfen: Bilastinum 6 mg/ml | A. Menarini GmbH | D | FB | | G |  |
| | FI | PI | | Imodium ‐ F - T | 20 Kapsel(n) | 3.87 | 6.85 | 40% | | Kapseln: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II (Switzerland) GmbH | D / SL / SO | FB | | G |  |
| | FI | PI | | Imodium - T | 60 Kapsel(n) | 9.40 | 26.60 | 40% | | Kapseln: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II (Switzerland) GmbH | B / SL / SO | FB | | G |  |
L | | FI | PI | | Microlax | 4 x 5 ml | 4.15 | 7.65 | 10% | | Klistier: 3 Wirkstoffe | JNTL Consumer Health II (Switzerland) GmbH | D / SL | FB | | G |  |
L | | FI | PI | | Microlax | 12 x 5 ml | 12.45 | 23.00 | 10% | | Klistier: 3 Wirkstoffe | JNTL Consumer Health II (Switzerland) GmbH | D / SL / LPPV | FB | | G |  |
L | | FI | PI | | Microlax | 50 x 5 ml | 51.88 | 95.80 | 10% | | Klistier: 3 Wirkstoffe | JNTL Consumer Health II (Switzerland) GmbH | D / SL / LPPV | FB | | G |  |
L | | FI | | | Vegzelma 100 mg/4 ml | | 257.57 | 296.55 | 10% | | Infusionskonzentrat: Bevacizumabum 100mg / 4ml | iQone Healthcare Switzerland SA | A / SL | FB | | G |  |
L | | FI | | | Vegzelma 400 mg/16 ml | | 962.84 | 1063.55 | 10% | | Infusionskonzentrat: Bevacizumabum 400mg / 16ml | iQone Healthcare Switzerland SA | A / SL | FB | | G |  |
L | | FI | PI | | D3 VitaCaps 24,000 IU (600 μg) | 6 | 7.65 | 17.55 | 10% | | Weichkapseln: Cholecalciferolum 600 µg | Pierre Fabre Pharma SA | B / SL | FB | | G |  |
L | | FI | | PS | Herceptin subkutan 600mg/5ml | | 1484.04 | 1630.40 | 10% | | Lösung zur subkutanen Injektion: Trastuzumabum 600mg / 5ml | Roche Pharma (Schweiz) AG | A / SL | FB | | G |  |
L | | FI | | | Ogivri 150 mg | | 456.84 | 513.25 | 10% | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 150 mg | Medius AG | A / SL | FB | | G |  |
| | FI | PI | | Imodium lingual akut | 10 | PA | PA | k.A. | | Schmelztabletten: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II (Switzerland) GmbH | D | FB | | G |  |
| | FI | PI | | Imodium lingual akut | 12 | PA | PA | k.A. | | Schmelztabletten: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II (Switzerland) GmbH | D | FB | | G |  |
| | FI | PI | | Nicorette Microtab Original-Aroma | 100 Tablette(n) | PA | PA | k.A. | | Sublingualtabletten: Nicotinum 2 mg | JNTL Consumer Health II (Switzerland) GmbH | D / LPPV | FB | | G |  |
| | FI | PI | | D3 VitaCaps 24,000 IU (600 μg) | 4 | PA | PA | k.A. | | Weichkapseln: Cholecalciferolum 600 µg | Pierre Fabre Pharma SA | B | FB | | G |  |
| | FI | PI | | D3 VitaCaps 24,000 IU (600 μg) | 8 | PA | PA | k.A. | | Weichkapseln: Cholecalciferolum 600 µg | Pierre Fabre Pharma SA | B | FB | | G |  |
| | FI | PI | | D3 VitaCaps 24,000 IU (600 μg) | 12 | PA | PA | k.A. | | Weichkapseln: Cholecalciferolum 600 µg | Pierre Fabre Pharma SA | B | FB | | G |  |
| | FI | PI | | Regaine 5 % | 60 ml | PA | PA | k.A. | | Lösung: Minoxidilum 50 mg/ml | JNTL Consumer Health II (Switzerland) GmbH | D / LPPV | FB | | G |  |
| | FI | PI | | Regaine 5 % | 3 x 60 ml | PA | PA | k.A. | | Lösung: Minoxidilum 50 mg/ml | JNTL Consumer Health II (Switzerland) GmbH | D / LPPV | FB | | G |  |
| | FI | | | Mylotarg 5 mg | | PA | PA | k.A. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Gemtuzumabum Ozogamicinum 5 mg | Pfizer AG | A | FB | | G |  |
|
L | | FI | | I/B | Varivax | Durchstechflasche(n) | 42.39 | 62.50 | 10% | | Injektionssuspension: Virus Varicellae Vivus (Stamm Oka) 1350 U | MSD Merck Sharp & Dohme AG | B / SL | FB | | G |  |
L | | FI | | I/B | Varilrix | | 41.30 | 61.35 | 10% | | Lyophilisat und Lösungsmittel: Virus Varicellae Vivus (Stamm Oka) 10 U | GlaxoSmithKline AG | B / SL | FB | | G |  |